van Veggel, Bianca <br/><br/>
Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.  [electronic resource] 

 -  Lung cancer (Amsterdam, Netherlands)  10 2018 
 - 130-134 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1872-8332 
<br/><br/><label>Standard No.: </label>10.1016/j.lungcan.2018.07.030  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Anaplastic Lymphoma Kinase--antagonists & inhibitors<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Crizotinib--pharmacology<br/>Drug Resistance, Neoplasm<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Gene Amplification<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation--genetics<br/>Protein Kinase Inhibitors--therapeutic use<br/>Proto-Oncogene Proteins c-met--antagonists & inhibitors<br/>Survival Analysis<br/>Treatment Outcome